Lupus (SLE) trials in United Kingdom

In United Kingdom 19 Also abroad 354

19 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Cambridge, Leeds, London, Newcastle upon Tyne, Sheffield
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Where
London, Newcastle upon Tyne
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Where
Doncaster, London, Walsall
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00
Phase 2Taking people
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Where
Glasgow, Liverpool, London
Age
5 years to 17 years
People
40 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05039619 · EU 2023-505825-15-00
Phase 3Taking people
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Where
Bath, Cambridge, Greater London, Newcastle upon Tyne, Peterborough, Reading, Southampton, Stoke-on-Trent, Swindon
Age
18 years to 75 years
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00
No phaseTaking people
Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study
Where
Cambridge
Age
18 years to 70 years
People
15
Run by
University of Cambridge
See details and how to joinNCT07913919
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Where
Bath, Belfast, Leeds, London, Newcastle upon Tyne, Sheffield, West Bromwich
Age
16 years and over
People
450 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00
No phaseTaking people
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Where
Bath, London, Oxford, Wolverhampton
Age
16 years and over
People
223 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07175285
Phase 2Taking people
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
Where
Birmingham, Bristol, Cambridge, Edinburgh, Glasgow, London, Manchester
Age
12 years to 65 years
People
35 worldwide
Run by
Autolus Limited
See details and how to joinNCT07053800 · EU 2024-519941-32-00
Phase 1Taking people
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Where
London
Age
18 years to 65 years
People
48 worldwide
Run by
AstraZeneca
See details and how to joinNCT07201558 · EU 2025-522273-10-00
Phase 2Taking people
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Where
Basingstoke, Belfast, Cambridge, Doncaster
Age
18 years to 74 years
People
405 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07409181 · EU 2025-523488-39-00
Phase 1Taking people
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Where
Glasgow, London, Southampton
Age
18 years to 70 years
People
72 worldwide
Run by
AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00
Phase 3Enrolling by invitation
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
Where
Cannock, Doncaster, London
Age
18 years and over
People
864 worldwide
Run by
Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00
Phase 2Taking people
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Where
Cambridge, Edinburgh, Leicester, Newcastle upon Tyne
Age
18 years to 75 years
People
220 worldwide
Run by
Amgen
See details and how to joinNCT06570798
Phase 3Taking people
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Where
Birmingham, Bristol, Liverpool, London, Manchester, Southampton
Age
5 years to 17 years
People
100 worldwide
Run by
AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00
Phase 1/2Taking people
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Where
Bristol
Age
18 years to 70 years
People
150 worldwide
Run by
AstraZeneca
See details and how to joinNCT06897930
Phase 1Taking people
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
Where
Cambridge, Liverpool, London, Middlesex
Age
18 years to 65 years
People
142 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06576271 · EU 2024-514186-18-00
Phase 1Taking people
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Where
Cambridge, London, Manchester
Age
12 years to 70 years
People
244 worldwide
Run by
Fate Therapeutics
See details and how to joinNCT06308978
No phaseTaking people
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
Where
London
Age
18 years to 45 years
People
700 worldwide
Run by
Hospital for Special Surgery, New York
See details and how to joinNCT00198068